The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').
A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine administration (3 to 6 mg per day) brought about marked improvement in 25% and an improvement in 55% of the patients. The results suggest that co-dergocrine could be a useful drug when combined with other bronchodilators in the treatment of bronchial asthma.
D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D001993:Bronchodilator Agents; D004088:Dihydroergotoxine